Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The combination of target drugs Tafinlar-Mekinist is approved for nearly any type of advanced solid tumor that has the BRAF gene mutation.
A combo treatment of Tafinlar and Mekinist may be better than chemo for some children with a brain cancer called low-grade glioma.
Combination therapy using Taflinar and Mekinst led to improved response for pediatric patients with low-grade gliomas
Tafinlar plus Mekinist shrank tumors in people with biliary tract cancer and adenocarcinoma of the small intestine.
Tafinlar and Mekinist approved for a third cancer with specific gene mutation.
People who received the combination treatment had a statistically significant improvement in relapse-free survival.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.